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Biopsy Related Prostate Status Does Not Affect on the
Clinicopathological Outcome of Robotic Assisted
Laparoscopic Radical Prostatectomy
I n t r o d u c t i o n
For patients suspicious for prostate cancer by screening surveillance,
the final diagnosis has been made by transrectal ultrasound-guided
biopsies of 6�14 cores according to the physician’s preference. After
the introduction of serum prostate specific antigen (PSA) into the
clinical screening strategy for prostate cancer, the stage at pathologic
confirmation has decreased. As a result, most of the diseases dis-
covered have been localized cancers (1). For these localized tumors,
radical prostatectomy (RP) is the standard established treatment option,
and the goals of RP in this stage are cancer cure, minimization of
complications and perioperative suffering, and preservation of urinary
continence and erectile function (2). 
To achieve these goals, urologists typically recommend that RP be
performed at least 4 to 6 weeks after biopsy in spite of the patient’s
anxiety for early operation (3). This delay presumably allows
inflammatory adhesions and hematomas to resolve, so that the
anatomic relationships between the prostate and its surrounding
structures return to a nearly normal state before surgery. In terms of
the number of biopsy cores, an increase over the traditional six cores is
required to improve tumor detection rate. However, this can
potentially aggravate the technical difficulty of RP by inducing
inflammation and bleeding. 
Cancer Res Treat. 2009;41(4):205-210
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
Purpose
To determine whether the biopsy core number and time interval between prostate biopsy and
radical prostatectomy affect the operative and oncologic outcome of robot assisted
laparoscopic radical prostatectomy (RALP).
Materials and Methods
From January 2008 to April 2009, a single surgeon performed 72 RALPs after an initial
learning period of 30 cases. The relationship between time from biopsy to prostatectomy and
biopsy core number with operative time and estimated blood loss (EBL) were initially
evaluated with a linear regression model. These patients were classified into groups
according to whether the interval from biopsy to RALP was within four weeks or not, and
whether there were less than or greater than 10 core specimens removed. 
Results
RALP was performed in 34 patients within four weeks of biopsy, and in 38 patients more than
4 weeks after biopsy. According to the number of core specimens removed, less than 10
cores were performed in 10 patients, and more than 10 cores were performed in 62 patients.
Using an interval of 4 weeks as the cutoff point, early surgery was associated with longer
operating time (232.6 vs 208.8 min) and increased estimated blood loss (305.1 vs 276.9 mL). For
cases with more than 10 biopsy cores, there was a slight increase in operative time (229.2 vs
210.3 min). None of these differences were statistically significant by multivariate analysis.
Conclusion
Our data suggests that there is no reason to delay RALP to more than 4 weeks after prostate
biopsy. It also revealed that the number of biopsy cores (up to 14) did not influence operative
outcome. Thus, RALP is a feasible procedure regardless of the biopsy related prostate state.   
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While there is no distinct surgical modality to resolve these
dilemmas related to prostate biopsy, robotic assisted laparoscopic
radical prostatectomy (RALP) can be a surgical approach that
maintains the goals of RP. RALP provides several benefits in precise
dissection through improved instrument control with articulating tips,
3-dimensional vision, and a magnified surgical field (4). If this new
modality enables safe and feasible operations regardless of biopsy
core number or the interval from biopsy to operation, it will provide
another advantage in biopsy strategy for both patient and physician,
widening surgical indications of RP. To evaluate the possible role of
RALP, we prospectively investigated the effect of biopsy related
prostate status on the clinicopathologic outcome of RALP in our
institution. 
M a t e r i a l s  a n d  M e t h o d s  
1 Patient and data analysis
From July 2007 to April 2009, 72 consecutive patients with
clinically localized or locally advanced prostate cancer underwent
RALP by a single surgeon (J. Cheon) after an initial learning period of
30 cases (5). For these patients, peri-operative variables including
prostate biopsy core number and interval to operation were collected
prospectively and analyzed. All patients had biopsy proven adeno-
carcinoma of the prostate, which were staged according to the 1992
American Joint Committee on Cancer (AJCC) classification (6). 
All patients underwent digital rectal examination, transrectal
ultrasonography, whole body bone scan, and abdominal CT or MRI
to determine preoperative stage. To investigate intra-operative
outcomes, the operative time (including console time and set up time),
and estimated blood loss were surveyed. In this series, the total
operative time was defined as the time from initial incision to skin
closure. Post-operatively, information on the hospital stay,
catheterization period, pathologic result (including positive surgical
margin), and development of complications were collected. 
The impact of biopsy core number and interval to RP on operative
time and EBL were evaluated initially by linear regression. To
evaluate the influences of the previously established recommendations
of a 4 week interval and a biopsy core number of 10, the patients were
sub classified into two groups according to the interval from biopsy to
surgery using a cutoff point of 4 weeks, and according to the total
number of biopsy cores with a cutoff point of 10 cores. Among these
groups, the differences in mean operation time, EBL, transfusion rate,
positive-margin rate, bladder neck reconstruction rate, and nerve-
sparing rate were evaluated by univariate analysis (Mann-Whitney U
test, Pearson’s chi-square test) and univariate Logistic regression
analysis. The statistical analysis program SPSS ver. 12.0 (SPSS,
Chicago, IL) was used, and a p-value below 0.05 was considered
statistically significant.
2 Surgical procedures
Surgery was performed by standard transperitoneal approach and
interfacial technique, as reported by Patel et al (7). The dorsal vein
complex was ligated with a 1-0 Monocryl stitch (Ethicon INC,
Cornelia, GA), and a second 1-0 Monocryl stitch was then placed
through the periurethral tissue and periosteum of the posterior pubic
symphysis, for anterior reconstruction. To optimize nerve sparing, all
prostatic pedicles were clipped with Hem-o-lok polymer ligating clips
(Weck Closure Systems, Research Triangle Park, NC), then sharply
divided. For the patient with planned nerve preservation, a
neurovascular bundle (NVB) sparing procedure was performed with
the method originally described by Patel (7). After the NVB was
released from the posterolateral aspect of the prostate, the dissection
was extended distally towards the prostatic apex. The attachment of the
NVB and prostate was then dissected in a retrograde manner, and then
divided after clipping. The urethrovesical anastomosis was performed
in a running fashion using a double-arm 3-0 Monocryl suture. 
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Table 1. Perioperative characteristics of enrolled patients
Variable Mean value Range
Age (years) 61.6 46�75
Boby mass index (kg/m2) 24.5 18�30
Time to RALP (weeks) 6.5 2�12
Biopsy core number 10.2 5�14
Preoperative PSA (ng/mL) 9.9 3.3�24.2
Prostate volume (g) 28.2 12�72
Clinical stage
T1 28 (38.8%)
T2 orT3 44 (61.2%)
Biopsy Gleason score 6.6 6�10
Mean operation time (min) 179.6 145�240
Mean set up time (min) 15.1 15�20
Mean console time (min) 182.9 120�395
Estimated blood loss (mL) 293.2 150�800








Surgical margin positive rate (%)
≤T2 1 (2.3%)
＞T2 19 (67.9%)
Indwelling foley catheter (days) 10.0 7�14
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Patient number or mean value Uni-variate analysis Multi-variate analysis
＜10 cores (n=12) ≥10 cores (n=60) p-value p-value Odds ratio
Age (yr) 62.1 62.0 0.57
PSA (ng/mL) 10.7 10.2 0.63
Prostate volume (g) 24.5 23.6 0.45
Clinical stage 0.59
T1 4 (33.3%) 19 (31.7%)
T2 or T3 8 (66.7%) 41 (68.3%)
Gleason sum
≤6 6 (50.0%) 27 (45.0%) 0.11
≥7 6 (50.0%) 33 (55.0%)
Mean operative time (min) 210.3 229.2* 0.04* 0.25 1.001
Mean estimated blood loss (mL) 285.1 294.8 0.13 0.31 0.998
Transfusion (%) 1 (8.3%) 4 (6.7%) 0.23 0.28 0.722
Bladder neck reconstruction (%) 2 (16.7%) 14 (23.3%) 0.39 0.17 1.532
NeuroVascularBundle preservation (%) 0.32 0.55 1.206
No 5 (41.7%) 24 (40.0%)
Unilateral 3 (25.0%) 20 (33.3%)
Bilateral 4 (33.3%) 16 (26.7%)
Indwelling foley catheter (days) 15.9 16.0 0.53 0.31 0.794
Hospital stay (days) 8.9 8.2 0.36 0.62 0.512
Surgical margin positive (%) 3 (25.0%) 17 (28.3%) 0.45 0.42 1.027
Complication (%) 1 (8.3%) 4 (6.7%) 0.61 0.37 0.841
Table 3. Operative outcomes stratified by biopsy core number
Patient number or mean value Uni-variate analysis Multi-variate analysis
≤4 weeks (n=34) ＞4 weeks (n=38) p-value p-value Odds ratio
Age (yr) 61.9 62.6 0.38
PSA (ng/mL) 9.9 10.1 0.63
Prostate volume (g) 27.7 29.1 0.75
Clinical stage 0.56
T1 13 (38.2%) 10 (26.3%)
T2 or T3 21 (61.8%) 18 (73.7%)
Gleason sum 0.12
≤6 12 (35.3%) 13 (34.2%)
≥7 22 (64.7%) 25 (65.8%)
Mean operative time (min) 232.6* 208.8 0.04* 0.07 1.005
Mean estimated blood loss (mL) 305.1* 276.9 0.03* 0.17 0.992
Transfusion rate (%) 2 (5.9%) 3 (7.9%) 0.69 0.66 0.673
Bladder neck reconstruction (%) 6 (17.6%) 10 (26.3%) 0.59 0.99 1.003
NeuroVascularBundle preservation (%) 0.28 0.65 1.143
No 13 (38.2%) 15 (39.5%) 
Unilateral 11 (32.6%) 13 (34.2%)
Bilateral 9 (29.2%) 11 (26.3%) 
Indwelling foley catheter (days) 15.9 16.0 0.41 0.29 0.872 
Hospital stay (days) 8.9 8.2 0.49 0.72 0.735
Surgical margin positive (%) 9 (26.5%) 11 (28.9%) 0.67 0.22 0.541
Complication (%) 2 (5.9%) 3 (7.9%) 0.58 0.45 0.972
Table 2. Operative outcomes stratified by time to RALP
*p＜0.05 by uni-variate analysis.
*p＜0.05 by uni-variate analysis.
R e s u l t s
RALP patient characteristics are summarized in Table 1. Mean age
(range) was 61.6 (46�75) years old and body mass index was 24.5
(18�30) kg/m2. The mean interval from biopsy to RALP was 6.5 (2
�12) weeks and the mean biopsy core number was 10.2 (5�14).
Mean operative time was 218.9 (170�350) minutes and mean EBL
(estimated blood loss) was 293.2 (150�800) mL. Bladder neck
reconstruction rate was 19.4% and nerve-sparing rate was 61.0%.
Lengths of hospital stay and foley catheter indwelling time were 17.0
and 8.6 days, respectively. A positive surgical margin was present in
only one of 44 patients with localized (≤pT2) tumors (2.3%). In this
patient, RALP was performed 6 weeks after a 10-core prostate biopsy. 
The complication rate was 6.9%. No patient had major compli-
cations such as open conversion, rectal injury, major vessel injury, or
thromboembolic diseases. Three patients had postoperative ileus (two
transient, one prolonged), and two patients had trocar insertion-related
subcutaneous hematomas. All of these minor complications were
resolved following conservative management.
After subdividing the patients into two groups, operative outcomes
were stratified by time interval to RALP and summarized in Table 2.
The resulting two groups had similar characteristics in age, pre-
operative PSA, prostate volume, tumor stage, and gleason score. The
mean intervals from biopsy to RP for the groups that underwent RP
within 4 weeks (n=34) and after 4 weeks (n=38) were 3.2 (2�4)
weeks and 8.3 (5�13) weeks, respectively. Mean operative time for
RALPs performed within 4 weeks was longer (232.6 min vs 208.8
min) than those performed after 4 weeks. EBL was greater for the
RALPs performed within 4 weeks (305.1 mL vs 276.9 mL), though
Cancer Res Treat. 2009;41(4):205-210
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Fig. 1. (A) Simple correlation analysis between interval from biopsy to RALP (weeks) and operative time (minute) (correlation coefficient 0.24,
p=0.09), (B) between interval from biopsy to RALP (weeks) and EBL (mL) (correlation coefficient 0.26, p=0.14).
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Fig. 2. (A) Simple correlation analysis between total number of tissue cores removed from biopsy and operative time (minute) (correlation
coefficient 0.10, p=0.35) , (B) between total number of tissue cores removed from biopsy and EBL (mL) (correlation coefficient 0.09, p=0.53).
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more transfusions were not needed. These differences were not
reproduced in a multi-variate analysis. Positive-margin rate,
complication rate, bladder neck reconstruction rate, nerve-sparing rate,
length of hospital stay, and indwelling foley catheter time showed no
difference regardless of interval to RP.  
Table 3 reveals operative differences according to biopsy core
numbers. These two groups were also similar in age, preoperative
PSA, prostate volume, tumor stage, and gleason score. The mean core
number less than 10 (n=10) was 6.3 (5�9) and the mean core number
greater than 10 (n=62) was 11.2 (10�14). In cases of extended
biopsy (more than 10 cores obtained), operative time was longer
(229.2 min vs 210.3 min), but no clinical significance was observed
on multi-variate analysis. Other clinical parameters were similar.
Thus, all the differences showed no statistical significance on uni-
variate analysis, and there were no actual increases in operative time
or EBL in cases with early operation or extended core biopsy.
Linear correlation analysis was used to compare the interval from
biopsy to RALP with both operative time and EBL, and there was no
correlation (correlation coefficient 0.24, p=0.09 and 0.26, p=0.14, Fig.
1). Similarly, the number of core specimens also showed no
relationship with either operative time or EBL (correlation coefficient
0.10, p=0.35 and 0.09, p=0.53, Fig. 2).
D i s c u s s i o n
Scheduling for radical prostatectomy (RP) after biopsy remains a
problematic decision. Many urologists contend that performing RP
soon after a biopsy increases surgical difficulty and complication
rates. Urologists have typically recommended that radical pro-
statectomy be performed at least 4 to 6 weeks after biopsy, pre-
sumably to allow for resolution of biopsy-induced inflammation and
bleeding. But the basis of this conception is limited. Imaging studies
by endorectal MRI after prostate biopsy suggest that changes can last
up to 21 days (8,9). The serum PSA level generally returns to baseline
4 weeks after biopsy, and is considered a sign of complete resolution
of inflammation (10). These findings support the concept of waiting a
minimum of 4 weeks before conducting an RP, and this was
empirically used as a guideline period. However, a recent report that
retrospectively reviewed the charts of 169 patient who had undergone
retropubic RP showed that the interval to RP is not associated with
operative time, length of hospital stay, or complications (11). The only
variable that approached statistical significance was EBL. Another
study of 2,996 patients did not find a significant association of shorter
intervals with EBL, operative time, positive surgical margins,
postoperative erectile dysfunction, or urinary incontinence (12). All
patients in the present analysis had retropubic RP, and these findings
are applicable to RP performed via the robotic or laparoscopic
approach (13,14). In addition, because many treatment options are
available for clinically localized prostate cancer, significant periods
are often required before finalizing the treatment choice decision. In
addition, most large studies have suggested that a delay between
biopsy and RP does not compromise postoperative disease-free
progression (15,16). Operative difficulties or bleeding may be
ascribable to local unresolved inflammation, or greater difficulty in
dissecting between tissue planes.
Our study revealed more information on this issue. In early RALP
done 2�4 weeks after biopsy, the operative time and EBL were
arithmetically increased compared to that in the delayed RALP group,
but these differences did not reach statistical significance. In contrast
to most reports that have been published, about 100 patients
underwent RALP in this study. This implies that surgical feasibility
and safety for early RP could be obtained during initial learning period
of the RALP, and this may be another advantage of this novel
modality. 
So the current recommendation of waiting 4-weeks or more from
biopsy to RP might not be necessary in all patients to guarantee a
reduction in operative complications, and early RP from prostate
biopsy does not appear to induce more technical difficulty in our
study. Because urologists often encounter impetuous patients that
choose RP and request a surgical date as soon as possible, these
findings may provide reassurance to urologists and patients that
choose RP relatively soon after biopsy. 
Biopsy core number usually has focused on the cancer detection
rate rather than surgical influences. Most urologists agree that the
sextant biopsy is inadequate and initial prostate biopsy strategies
should include at least 10�14 cores. To improve prostate cancer
detection, more than 10 core extended biopsy protocols were
developed. Presti et al. prospectively evaluated 10-core biopsy in 483
patients and found that sextant biopsy alone was inadequate, as 20%
of cancers were missed (17). Six-core biopsy detected only 71% of
cancers found by 12-core biopsy (18). Short term complications from
biopsy were similar. Berger et al. compared complication rates
between 6, 10, and 15-core biopsy protocols (19). Their study
revealed no difference in major complications (fever, prostatitis,
epididymitis, or urinary retention), although there was an increased
number of patients with hematospermia after 10-core and 15-core
biopsies. The mean number of tissue cores obtained at diagnostic
prostate biopsy increased from 6.9 in 1995 to 10.2 in 2004. The trend
toward an increasing number of removed cores may have contributed
indirectly to improved outcomes after RP by decreasing the
percentage of positive cores and being associated with recurrence-free
survival after radical prostatectomy (20). But the effect of an increased
biopsy core number compared to conventional sextant biopsies on
surgical outcome (including operative time and blood loss) remains
unclear. The increased number of biopsy cores did not influence the
operative parameters in our study except for a comparatively longer
operative time. Extended biopsy includes conventional sextant biopsy
cores - at the base, mid-gland, and apex of the prostate - and additional
cores laterally directed at the base, mid-lobar and apex. These extra
cores have a more superficial location, so we can better predict
adhesive tissue effect and inflammation from biopsy. The effect of an
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increased biopsy core number on operation was negligible in our study. 
This report on biopsy core number and time from biopsy to
operation in RALP has limitations. There is lack of analysis in
functional outcome regarding potency and continence due to a
relatively short follow up period. Also, while the positive surgical
margin was similar in each group, information on long term oncologic
safety in terms of biologic recurrence is still needed. Furthermore,
many biopsies were conducted in different hospitals with different
methods. In spite of these limitations, this study on biopsy core
number and the interval between prostate biopsy to RALP gives
positive support to patients who are anxious for quick operations and
more extensive biopsies to cure their disease. According to our results,
clinicians could be more free to select the time of RALP and less
distressed about prostate condition from increased biopsy core
numbers in RALP. 
C o n c l u s i o n
In our data, advancing the time of RALP to 2�4 weeks after
biopsy did not impact surgical and pathologic outcomes compared to
the conventional delay of over 4 weeks. Similarly, extension of biopsy
core number to 14 cores did not influence the short term result of
RALP. These together imply that RALP can be conducted feasibly
regardless of biopsy related prostate status. However, longer and
larger studies would be needed to support this concept shift,
particularly in terms of functional and biological recurrence. 
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